E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
|
|
- Octavia Marylou Barrett
- 5 years ago
- Views:
Transcription
1 E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan
2 The Allergic Inflammatory Cascade B Cell Plasma Cell Mast Cell Second Allergen Exposure IgE Cytokines IL-4, IL-13 IgE crosslinked by allergen Antigen Presenting Cell T Cell First Allergen Exposure AR and Asthma Symptoms & Exacerbation Histamine Leukotriene Prostaglandins Cytokines Mast Cell Degranulation
3 Mast cells can induce IgE synthesis in B cells NMC (PAR) (n=8) T cell (PAR) (n=3) NMC +ail-4 (n=5) NMC +ail-13 (n=5) T cell + ail-4 (n=5) T cell + ail-13 (n=5) < 2 < T otal IgE (ng/ml) 3 Ag IgE FceRI IL-4/ IL-13 Mc CD4L CD4 B CD4-CD4L IgE class switch sige Pawankar R et al. J Clin Invest Pawankar R et al, Clin Exp Allergy Pawankar R. Curr Opin Allergy Immunol,
4 IgE is locally produced in the target organ CD2+ IL-4+ IgE Ce mrna+ CD2 + Durham et al. Eur Resp J
5 Binding of IgE to high-affinity (FceRI) receptor Twenty-five years later the receptors that mediate the binding of IgE to cells were described. Allergen binding site Ce1 V H C L V L IgE Although FceRI is expressed on monocytes and dendritic cells (and other cell types), its expression level is 1-1 fold less than in mast cells and basophils. FceRI Ce2 Ce3 a 2 a 1 Ce4 out Cell membrane a b g g in Holgate ST. QJM 1998
6 Fc epsilon RI expression in NMC % 1 ** Pawankar R et al J Clin Invest, 1997 PAR CIR
7 E-7 High-affinity IgE receptor-bearing cells in atopic and non-atopic asthma FcεRIα mrna+ cells (x 1 6 cells) obtained from 12mL BAL 17 FcεRI+ cells/mm 2 18 p=.1 p= p= p= Saline Allergen Saline Allergen Atopic Non-atopic Atopic Non-atopic Asthmatics Controls Asthmatics Controls Rajakulasingam K. Am J Respir Crit Care Med 1998 Humbert M. Am J Respir Crit Care Med 1996
8 pg/ ml pg/ ml IL-4 + IgE enhance mediator release from NMC 1 pg/ ml histamine release (%) ** ** ** ** ** IL-6 ** CIR (fr eshly isolated) CIR untreated & sensitized IL-4+IgE-treated & sensitized ** p < ** ** ** ** ** Pawankar R Clin Exp All IL-4 IL-13
9 Mast cell-ige-ige receptor axis Mc Ag IgE Mc Ag Ag Mc IL-4 Ag Mc
10 The prevalence of asthma is related to the level of serum IgE standardized for age and sex Prevalence of asthma (%) 4 Age 6 to <35 years n =2657 of the general population with self-reported asthma or allergic rhinitis 3 Age 35 to <55 years Age 55+ years 2 1 < <.5.5 <.5.5 < In all age groups, there was Ranges a highly of serum significant IgE Z score trend for prevalence to increase with increasing Z scores (p<.1). Burrows B et al. N Engl J Med 1989
11 FceRI-mediated Thymic Stromal Lymphopoietin Production by IL-4-primed Human Mast Cells E-11
12 Function of Thymic stromal lymphopoietin (TSLP ) E-12 Induction of T H 2- attracting chemokines CCL17, CCL22 Promotion of development of B22+ IgM+ immature B cells from pre-b cells Priming of naïve T H 2 cells to produce T H 2 cytokines A weak comitogen for T cell proliferation CD4+T cell development
13 TSLP as a key initiator of allergic inflammation TSLPR KO mice fail to develop an inflammatory lung response to inhaled antigen. E-13 Humans TSLP is expressed in epithelial cells of patients with atopic dermatitis The number of cells within the bronchial epithelium and submucosa expressing mrna for TSLP are significantly increased in asthmatics as compared with controls. Mice Skin-specific overexpression of TSLP results in an atopic dermatitis-like phenotype. Lung-specific overexpression of TSLP induces asthmalike airway inflammation.
14 TSLP expression by human bronchial mucosal mast cells of asthmatic patients TSLP Lumen Merged Tryptase (mast cells)
15 Significant increase in number of TSLP + Tryptase + cells in the airways of asthmatic patients A *** 1 Control Asthma B C 4 *** Control Asthma D *** F Control Asthma *** Control Asthma G Atopic * Non-Atopic
16 I-39 (ng/ml) TSLP (pg/ml) TSLP production by human mast cells following aggregation of FceRI in the presence of IL-4 1 b) IgE+IL4 wash Anti-IgE with DMSO -48h IgE+IL4 wash wash with DMSO Anti-IgE with PIC 16 h c) ** * * a-ige - + d) a- IgE
17 Correlation of % of TSLP + cells in mast cells with the serum IgE level, and hyperresponsibility in asthmatic patients and controls 1 8 r 2 =.131 P = r 2 =.252 P = IgE (U/ml) log1 Acetylcholine (mg/ml)
18 The number of AREG + tryptase + cells increases in bronchial mucosa of subjects with asthma
19 Correlation between AREG + tryptase + cells with the extent of goblet cell hyperplasia in the airways of asthmatic subjects Mucus score= n 1 + 2n 2 Grade 1 Goblet cell height epithelial layer <(1/3) Grade 2 Goblet cell height epithelial layer>1/3 n 1 ; Grade 1-cell count n 2 ; Grade 2 cell count (Tokuyama K et al Am J Physiol 199)
20 Rationale for anti-ige therapy Anti-IgE stops IgE binding to effector cells Allergen IgE synthesis Mast cell degranulation Inflammatory mediators Clinical symptoms Allergic rhinitis Mechanism Asthma Atopic eczema, urticaria Food allergy Treatment Allergen avoidance Hyposensitization Mast-cell stabilization: cromones, isoprenaline Mediator antagonists: antihistamines, antileukotrienes Late-phase inhibitors: steroids Adapted from Roitt J. Essential Immunology 1994
21 Immunohistochemical staining of bronchial biopsy specimens before (left) and after (right) 16 weeks of omalizumab treatment. Representative sections show staining with antibody against: ECP (A and B) Cell-surface IgE (C and D) High-affinity IgE R (E and F) IL-4 (G and H) Djukanović R, et al. Am J Respir Crit Care Med 24;17:
22 Mechanisms of Action of Omalizumab Reduces serum levels of free IgE Down-regulates expression of IgE receptors (FceRI) on mast cells and basophils. In the airways of patients with allergic asthma, it reduces FcεRI+ and IgE+ cells and causes a profound reduction in tissue eosinophilia, together with reductions in submucosal T-cell and B-cell numbers. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. J Allergy Clin Immunol 25;115(3):
23 Mechanisms of action of omalizumab (cont d) The reductions in circulating levels of IgE resulting from omalizumab treatment leads to reductions in FceRI expression on mast cells, basophils and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia, levels of GM-CSF, IL-2, IL-4, IL-5 and IL-13. It may also reduce allergen presentation to T- cells and the production of Th2 cytokines. Holgate S, et al. Allergy 29:64(12):
24 Forced expiratory volume in 1 second as a percentage of baseline in the placebo (A) and omalizumab (B) groups. van Rensen E, et al. Allergy 29;64:72 8.
25 Effect of add-on therapy with omalizumab in patients with severe persistent asthma whose asthma was inadequately controlled by therapy with high-dose ICSs plus a LABA Humbert M, et al. Allergy 25; 6:39 16
26 Conclusion Benefits of Anti-IgE in atopic disease E-26 Effectively reduces the incidence of allergic asthma exacerbations while decreasing the need for steroids Improves asthma-specific QoL and reduces the incidence of hospitalizations Can simplify the control of asthma with only once or twice monthly injections Controls the symptoms of SAR, reducing the requirement for concomitant medication Has a good long-term safety profile
27 WAO White Book on Allergy Allergic Diseases as a Global Public Health Issue Authored by: International expert allergists and clinical immunologists; has been compiled for publication under the supervision of the WAO Education Council. Purpose: To serve as a major resource in explaining allergic diseases, their prevalence, management, and the importance of adequate service provision for allergy patients. Edited by Professors Ruby Pawankar, Stephen T. Holgate, G. Walter Canonica, and Richard F. Lockey
28
29 E-29
30 E-3
Searching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationAirway Inflammation in Asthma Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan.
REVIEW ARTICLE Chih-Yung Chiu 1,2, Kin-Sun Wong 2 1 Department of Pediatrics, Chang Gung Memorial Hospital, Keelung, Taiwan. 2 Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationDefining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness
Defining Asthma: Clinical Criteria Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine, 2nd ed. Murray, Nadel, eds.(saunders:philadelphia)
More informationDefining Asthma: Clinical Criteria. Defining Asthma: Bronchial Hyperresponsiveness
Defining Asthma: Clinical Criteria Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine, 2nd ed. Murray, Nadel, eds.(saunders:philadelphia)
More informationDefining Asthma: Bronchial Hyperresponsiveness. Defining Asthma: Clinical Criteria. Impaired Ventilation in Asthma. Dynamic Imaging of Asthma
Defining Asthma: Clinical Criteria Defining Asthma: Bronchial Hyperresponsiveness Atopy 34% Recent wheeze 20% Asthma 11% AHR 19% n = 807 From: Woolcock, AJ. Asthma in Textbook of Respiratory Medicine,
More informationAnti-IgE Treatment In Severe Asthma. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Anti-IgE Treatment In Severe Asthma Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Relevant Disclosures Financial Relationship/Consulting Fees: Value
More informationAnti-IgE: beyond asthma
Anti-IgE: beyond asthma Yehia El-Gamal, MD, PhD, FAAAAI Professor of Pediatrics Pediatric Allergy and Immunology Unit Children s Hospital, Ain Shams University Member, WAO Board of Directors Disclosure
More informationImplications on therapy. Prof. of Medicine and Allergy Faculty of Medicine, Cairo University
Implications on therapy Dr. Hisham Tarraf MD,FRCP(Edinb.) Prof. of Medicine and Allergy Faculty of Medicine, Cairo University Need for better understanding Global health problem Impact on quality of life
More informationDiagnosis and Management of Fungal Allergy Monday, 9-139
Diagnosis and Management of Fungal Allergy Monday, 9-139 13-2010 Alan P. Knutsen,, MD Director, Pediatric Allergy & Immunology Director, Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies
More informationDNA vaccine, peripheral T-cell tolerance modulation 185
Subject Index Airway hyperresponsiveness (AHR) animal models 41 43 asthma inhibition 45 overview 41 mast cell modulation of T-cells 62 64 respiratory tolerance 40, 41 Tregs inhibition role 44 respiratory
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!
More informationand its clinical implications
The Immunology of Allergy and its clinical implications By Dr Priya Bowry Sikand MBBS MRCGP DFFP DIC MSc(Allergy) Back to the Basics. Objectives Understand immunological mechanisms behind Type 1 Hypersensitivity
More informationAdd on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes
Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective
More informationHow immunology informs the design of immunotherapeutics.
How immunology informs the design of immunotherapeutics. Stephen R Durham Allergy and Clinical Immunology, Royal Brompton Hospital and Imperial College London WAO Cancun Mon Dec 5 th 2011 How immunology
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationDr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline
Pathology of Asthma Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline Bronchial Asthma Definition: chronic, relapsing inflammatory lung disorder characterised by reversible
More informationSafety, PK and PD of ARRY-502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies
Safety, PK and PD of ARRY502, a CRTh2 Antagonist, in Healthy Subjects with a History of Seasonal Allergies L. Burgess*, L. Anderson, C. Nugent, N. Klopfenstein, C. Eberhardt, L. Carter, C. Kass, S. RojasCaro,
More informationUpdate on Biologicals for ABPA and Asthma
Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA Disease of chronic airway
More informationAllergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis
Hypersensitivity Disorders Hypersensitivity Disorders Immune Response IgE Disease Example Ragweed hay fever IgG Cytotoxic Immune complex T Cell Hemolytic anemia Serum sickness Poison ivy IgE-mediated Diseases
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationSystems Pharmacology Respiratory Pharmacology. Lecture series : General outline
Systems Pharmacology 3320 2017 Respiratory Pharmacology Associate Professor Peter Henry (Rm 1.34) Peter.Henry@uwa.edu.au Division of Pharmacology, School of Biomedical Sciences Lecture series : General
More informationMechanisms of action of bronchial provocation testing
Mechanisms of action of bronchial provocation testing TSANZ / ANZSRS Masterclass: April 3rd, 2016 13:00 13:30 John D. Brannan PhD Scientific Director - Dept. Respiratory & Sleep Medicine John Hunter Hospital,
More informationTargeted IgE Therapy for Patients With Moderate to Severe Asthma
Targeted IgE Therapy for Patients With Moderate to Severe Asthma Bradley E. Chipps, MD Medical Director, Capital Allergy and Respiratory Disease Center, Sacramento, Calif. Patricia L. Marshik, PharmD Assistant
More informationProperty of Presenter
Have We Missed A Role For Neutrophils In Asthma? In Steroid-Refractory Asthma? Erwin W. Gelfand, MD Chairman, Department of Pediatrics National Jewish Health Professor of Pediatrics and Immunology University
More informationPotent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis
Potent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis Laura L. Carter, Yoshi Shiraishi, Yooseob Shin, Laurence Burgess, Christine Eberhardt,
More informationMast Cell Mediators. Updates on Chronic Urticaria 11/1/2016. Urticaria: What happens in the skin?
Urticaria: What happens in the skin? Updates on Chronic Urticaria Kent Woo, MD (USA) Allergy/Immunology Internal Medicine C A U S E MC, mast cell IgE Fc eri MC Release of Mediators Activation Vasodilation
More informationRising Incidence of Asthma
Controlling Severe Asthma through Advanced Diagnosis and Treatment Strategies James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationAllergic diseases and treatment. Feng Qian ( 钱峰 )
Allergic diseases and treatment Feng Qian ( 钱峰 ) fengqian@sjtu.edu.cn Hypersensitivity Antigen Host Adaptive responses protective to the host harmful to the host The deleterious consequences of the adaptive
More informationIn review. Mechanisms mediating pediatric severe asthma and potential novel therapies. Aldara Martin Alonso 1 1, 2* , Sejal Saglani
Mechanisms mediating pediatric severe asthma and potential novel therapies Aldara Martin Alonso 1 1, 2*, Sejal Saglani 1 National Heart and Lung Institute, Imperial College London, United Kingdom, 2 Respiratory
More informationDistinction and Overlap. Allergy Dpt, 2 nd Pediatric Clinic, University of Athens
Asthma Phenotypes: Distinction and Overlap Nikos Papadopoulos Allergy Dpt, 2 nd Pediatric Clinic, University of Athens Asthma as a syndrome From the Iliad to ADAM 33 and back again Bronchoconstriction,
More information12/22/13. Conflict of Interest. Acknowledgements. AERD as a Disease of Excessive Cysteinyl Leukotriene Production and Responsiveness
The Surprising Role of IFN-γ in AERD Larry Borish, M.D. Professor of Medicine Asthma and Allergic Disease Center University of Virginia Charlottesville, VA Conflict of Interest Grant Support: NIH, Dupont
More informationJamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
More informationIgE-mediated allergy in elderly patients with asthma
Allergology international (1997) 46: 237-241 Original Article IgE-mediated allergy in elderly patients with asthma Fumihiro Mitsunobu, Takashi Mifune, Yasuhiro Hosaki, Kouzou Ashida, Hirofumi Tsugeno,
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline Consensus characteristics/incidence data Immune/inflammatory basis Etiology/Genetic basis Hygiene
More informationDecember 7, 2010 Future Use of Biologics in Allergy and Asthma
December 7, 2010 Future Use of Biologics in Allergy and Asthma Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens
More informationAllergy overview. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
Allergy overview Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Adaptive Immune Responses Adaptive immune responses allow responses against
More informationRecognition & Management of Anaphylaxis in the Community. S. Shahzad Mustafa, MD, FAAAAI
Recognition & Management of Anaphylaxis in the Community S. Shahzad Mustafa, MD, FAAAAI Disclosures None Outline Define anaphylaxis Pathophysiology Common causes Recognition and Management Definition Acute,
More informationThe Skinny of the Immune System
The Skinny of the Immune System Robert Hostoffer, DO, FACOP, FAAP Associate Professor of Pediatrics Case Western Reserve University, Cleveland, Ohio Overview 1. Immune system of the skin 2. Immune Players
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationOmalizumab for Asthma
clinical therapeutics Omalizumab for Asthma Robert C. Strunk, M.D., and Gordon R. Bloomberg, M.D. This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAllergic Disorders. Allergic Disorders. IgE-dependent Release of Inflammatory Mediators. TH1/TH2 Paradigm
Allergic Disorders Anne-Marie Irani, MD Virginia Commonwealth University Allergic Disorders IgE-mediated immune reactions Clinical entities include: asthma allergic rhinitis atopic dermatitis urticaria
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationRESPIRATORY BLOCK. Bronchial Asthma. Dr. Maha Arafah Department of Pathology KSU
RESPIRATORY BLOCK Bronchial Asthma Dr. Maha Arafah Department of Pathology KSU marafah@ksu.edu.sa Jan 2018 Objectives Define asthma (BA) Know the two types of asthma 1. Extrinsic or atopic allergic 2.
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationXolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below
More informationThe g c Family of Cytokines Prof. Warren J. Leonard M.D.
The Family of Cytokines Chief, Laboratory of Molecular Immunology Director, Immunology Center National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services
More informationOriginal Research Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort
Original Research Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort David Haile-Meskale 1, Ron Olivenstein, MD 2,3, Toby Mcgovern, PhD 3, Cathy Fugere 3, James G. Martin, MD
More informationThe role of dendritic cells in asthma
Mechanisms of allergic diseases Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, William T. Shearer, MD, and Donata Vercelli, MD The role of dendritic cells in asthma Michelle Ann Gill, MD, PhD
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationTHE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
More informationInternational Journal of Pharma and Bio Sciences OMALIZUMAB: CURRENT STATUS IN ASTHMA THERAPY ABSTRACT
Review Article Pharmacology International Journal of Pharma and Bio Sciences ISSN 0975-6299 OMALIZUMAB: CURRENT STATUS IN ASTHMA THERAPY VIKAS SETH * AND SHAILESH YADAV Department of Pharmacology, Mayo
More informationChronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines
Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis ACCP Evidence-Based Clinical Practice Guidelines Christopher E. Brightling, MBBS, PhD, FCCP Objectives: Nonasthmatic eosinophilic bronchitis is
More informationEmerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationSporadic Antihistamine-Resistant Angioedema Potential Pathophysiological Mechanisms
Sporadic Antihistamine-Resistant Angioedema Potential Pathophysiological Mechanisms Massimo Triggiani, MD, PhD Division of Allergy and Clinical Immunology University of Salerno HAWK Consensus Meeting Gargnano,
More informationTARGETING THE IL-33/ST2 PATHWAY IN ASTHMA -IMPLICATIONS FOR DEVELOPMENT, EXACERBATION AND TREATMENT-
From THE DEPARTMENT OF MEDICINE SOLNA Karolinska Institutet, Stockholm, Sweden TARGETING THE IL-33/ST2 PATHWAY IN ASTHMA -IMPLICATIONS FOR DEVELOPMENT, EXACERBATION AND TREATMENT- Anna Zoltowska Nilsson
More informationNew Test ANNOUNCEMENT
March 2003 W New Test ANNOUNCEMENT A Mayo Reference Services Publication Pediatric Allergy Screen
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More information7/25/2016. Use of Epinephrine in the Community. Knowledge Amongst Paramedics. Knowledge Amongst Paramedics survey of 3479 paramedics
Recognition & Management of Anaphylaxis in the Community S. Shahzad Mustafa, MD, FAAAAI Disclosures Speaker s bureau Genentech, Teva Consultant Genentech, Teva Outline Knowledge gap Definition Pathophysiology
More informationAsthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,
Asthma Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital Figure 1 Asthma Prevalence, 1980-2000 * Gap between 1995-1996 and 1997 indicates a break in trend due to
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationU N I V E R S I T Ä T S M E D I Z I N B E R L I N
U N I V E R S I T Ä T S M E D I Z I N B E R L I N Chronic Urticaria: the role of mast cells and basophils Marcus Maurer Allergie-Centrum-Charité Department of Dermatology and Allergy Charité - Universitätsmedizin
More informationInduced sputum to assess airway inflammation: a study of reproducibility
Clinical and Experimental Allergy. 1997. Volume 27. pages 1138-1144 Induced sputum to assess airway inflammation: a study of reproducibility A. SPANEVELLO, G. B. MIGLIORI. A. SHARARA*, L. BALLARDlNIt,
More informationBiologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
More informationFormat. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
More informationCOPYRIGHTED MATERIAL. Definition and Pathology CHAPTER 1. John Rees
CHAPTER 1 Definition and Pathology John Rees Sherman Education Centre, Guy s Hospital, London, UK OVERVIEW Asthma is an overall descriptive term but there are a number of more or less distinct phenotypes
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationSeasonal Allergic Rhinoconjunctivitis
Seasonal Allergic Rhinoconjunctivitis Allergic rhinoconjunctivitis is a common condition. Most patients can achieve good symptom control through allergen avoidance and pharmacotherapy with non-sedating
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More information2010 Health Press Ltd.
Fast Facts Fast Facts: Asthma Third edition Stephen T Holgate MD DSc FRCP FMedSci MRC Clinical Professor of Immunopharmacology School of Medicine Southampton General Hospital Southampton, UK Jo Douglass
More informationASTHMA ASTHMA DISEASE SUMMARY. Risk Factors
ASTHMA Risk Factors Family history of asthma or other atopic diseases (eczema, hayfever) Having eczema or hayfever currently or as a child Living in an industrialised area more exposure to airborne pollutants,
More informationComparative Study of Nasal Smear and Biopsy in Patients of Allergic Rhinitis
Indian J Allergy Asthma Immunol 2002; 16(1) : 27-31 Comparative Study of Nasal Smear and Biopsy in Patients of Allergic Rhinitis Rakesh Chanda, Ajay Kumar Aggarwal, G.S. Kohli, T.S. Jaswal*, and K.B. Gupta**
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationEvolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT
Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,
More informationSLIT: Review and Update
SLIT: Review and Update Disclosure Speaker: ISTA Pharmaceuticals Speaker: GlaxoSmithKline Allergen IT - Evidence Based Evaluation: Rescue Medications Meta-analysis Disease IT # of Patients Rescue Medication
More informationTreating moderate-to-severe allergic asthma with anti- IgE monoclonal antibody (omalizumab). An Update
R E V I E W Eur Ann Allergy Clin Immunol VOL 42, N 4, 135-140, 2010 G. D Amato 1, M. Perticone 2, E. Bucchioni 2, A. Salzillo 1, M. D Amato 3, G. Liccardi 1 Treating moderate-to-severe allergic asthma
More informationUPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER
JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA OBJECTIVES Describe Describe asthma medications that have been added
More information10/24/2016. Precision Management of Severe Asthma How, When and Where. The Goals of Today s Presentation
1/24/216 Precision Management of Severe Asthma How, When and Where. Reynold A. Panettieri, Jr., MD Vice Chancellor for Clinical & Translational Science Director, Rutgers Institute for Translational and
More informationAnti-IgE for chronic asthma in adults and children (Review)
Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2007, Issue 4
More informationPharmacology of the Respiratory Tract: Allergy and IgE
Pharmacology of the Respiratory Tract: Allergy and IgE Tillie-Louise Hackett Assistant Professor, Department of Pharmacology James Hogg Research Centre University of British Columbia Short Synopsis This
More informationUNIVERSITY OF ZAGREB SCHOOL OF MEDICINE. Plan of the course. Basics of Pediatric Allergy. Academic year 2015/2016. Mirjana Turkalj
UNIVERSITY OF ZAGREB SCHOOL OF MEDICINE Plan of the course Basics of Pediatric Allergy Academic year 2015/2016 I. COURSE AIMS COURSE OUTLINE The specialty of allergy involves the management of a wide range
More informationManagement of Bronchial Asthma in Adults..emerging role of anti-leukotriene
Management of Bronchial Asthma in Adults..emerging role of anti-leukotriene Han-Pin Kuo MD, PhD Department of Thoracic Medicine Chang Gung University Chang Gung Memorial Hospital Taipei, Taiwan Bronchial
More informationRegulation of Type 2 Immunity by Basophils Prof. Dr. David Voehringer
Regulation of Type 2 Immunity by Basophils Department of Infection Biology Institute of Clinical Microbiology, Immunology and Hygiene Outline of the presentation The concept of type 2 immunity Basophil
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationRecent insights into atopic dermatitis and implications for management of infectious complications
Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado School of Medicine Denver, Colorado USA Recent insights into atopic
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationDistribution and degranulation of airway mast cells in normal and asthmatic subjects
Eur Respir J 22; 19: 879 885 DOI: 1.1183/931936.2.27582 Printed in UK all rights reserved Copyright #ERS Journals Ltd 22 European Respiratory Journal ISSN 93-1936 Distribution and degranulation of airway
More informationReview Article Airway Epithelium in Atopic and Nonatopic Asthma: Similarities and Differences
International Scholarly Research Network ISRN Allergy Volume 2011, Article ID 195846, 7 pages doi:10.5402/2011/195846 Review Article Airway Epithelium in Atopic and Nonatopic Asthma: Similarities and Differences
More informationLecture 2. Immunoglobulin
Lecture 2 Immunoglobulin Objectives; Define secretary IgA Describe structure & functions of IgM Compare the antigenic receptor of B lymphocyte Assess the role of IgE in Atopy Distinguish between Isotype,
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationNew Horizons Session on Specific Immunotherapy (SIT) Session 4: Practical considerations for SIT. When should SIT be started and why?
New Horizons Session on Specific Immunotherapy (SIT) Session 4: Practical considerations for SIT When should SIT be started and why? Lars Jacobsen: Research Centre for Prevention and Health Glostrup University
More informationcontact activation in formation diseases 67 endothelial cells and kinin formation 73 processing and degradation 68 70
Subject Index Adenosine, mast cell activation modulation 60 Age, risk factor 17, 18 Allergen elicitors 9, 10 insects, see Insect venom-induced microarrays for 136 overview of characteristics 23 recognition
More information2013 Health Press Ltd.
Fast Facts Fast Facts: Asthma Fourth edition Stephen T Holgate MD DSc FRCP FMedSci MRC Clinical Professor of Immunopharmacology School of Medicine Southampton General Hospital Southampton, UK Jo A Douglass
More information